Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $0.2552W HIGH $1.12
Volume
2.75 M
Value Traded
319.32 K
Short % Float
11.38%
-11.11%Week
-43.94%1 Month
-53.1%3 Month
-69.33%6 Month
-88.96%5 Year
-99.98%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
25.04 M
EPS (TTM)
-0.62
P/E Ratio
-
Ent. Value
-32.38 M
Total Shares
98.04 M
Float Shares
93.76 M
Insiders
4.41%
Institutions
38.13%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
ATYR Catalyst Timeline
Dated clinical, regulatory and corporate events for aTyr Pharma, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for aTyr Pharma, Inc.
637Total events
9Upcoming
81Tier-1 (high impact)
2016 to 2028Coverage
Upcoming catalysts 2
Event history 50
▲FDA Feedback ReceivedEfzofitimod/kgFDA Meeting
FDA feedback received on planned Phase 3 protocol for efzofitimod in pulmonary sarcoidosis
pulmonary sarcoidosissource ↗
▲Enrollment CompleteEfzofitimod/kgTrial
Enrollment completed in Phase 2 EFZO-CONNECT study
SSc-ILDsource ↗
▲Poster PresentationEfzofitimod/kgPresentation
Poster presented at WASOG 2026 Congress
pulmonary sarcoidosissource ↗
◆FDA Feedback ReceivedEfzofitimod/kgFDA Meeting
FDA feedback on Phase 3 protocol expected by end of August 2026
pulmonary sarcoidosissource ↗
◆Poster PresentationEfzofitimod/kgPresentation
Poster presentation of subgroup analysis of Phase 3 EFZO-FIT study at WASOG 2026
pulmonary sarcoidosissource ↗
▲Subgroup AnalysisEfzofitimod/kgClinical Data
Subgroup analysis of restrictive lung disease patients from EFZO-FIT shows clinically meaningful benefit in FVC and PROs for 5.0 mg/kg efzofitimod
pulmonary sarcoidosissource ↗
●Poster PresentationATYR0101Presentation
Poster presentation on ATYR0101 at Extracellular Matrix Pharmacology Congress
fibrosissource ↗
●IND SubmissionEfzofitimod/kgIND
Protocol submitted to FDA for planned Phase 3 study
pulmonary sarcoidosissource ↗
●Type C MeetingEfzofitimod/kgFDA Meeting
FDA Type C Meeting to inform future efzofitimod development
pulmonary sarcoidosissource ↗
●Trial InitiationEfzofitimod/kgTrial
EFZO-CONNECT Phase 2 trial in SSc-ILD advancing
systemic sclerosis-associated interstitial lung disease (SSc-ILD)source ↗
●Protocol AmendmentEfzofitimod/kgTrial
Protocol submitted to FDA for planned Phase 3 study in restrictive lung disease patients
pulmonary sarcoidosis with restrictive lung diseasesource ↗
◆Oral PresentationPresentation
RBC Capital Markets Global Healthcare Conference 1x1 Investor Meetings
◆Type C MeetingEfzofitimod/kgFDA Meeting
Type C meeting with FDA to review Phase 3 EFZO-FIT results and determine path forward
pulmonary sarcoidosissource ↗
◆Type C MeetingEfzofitimod/kgFDA Meeting
FDA Type C meeting to review Phase 3 EFZO-FIT study results and determine next steps
pulmonary sarcoidosissource ↗
●Oral PresentationPresentation
Conference call and webcast to discuss regulatory and clinical update
◆Type C MeetingEfzofitimod/kgFDA Meeting
FDA Type C meeting to discuss efzofitimod Phase 3 results and path forward
pulmonary sarcoidosissource ↗
◆Oral PresentationPresentation
aTyr Pharma to present at Leerink Partners Global Healthcare Conference
▼Primary Endpoint MissedEfzofitimod/kgClinical Data
Phase 3 EFZO-FIT study did not meet primary endpoint
pulmonary sarcoidosissource ↗
◆Type B MeetingEfzofitimod/kgFDA Meeting
FDA meeting to review EFZO-FIT results and determine path forward
pulmonary sarcoidosissource ↗
◆First Patient DosedEfzofitimod/kgTrial
FDA meeting to determine path forward for efzofitimod in pulmonary sarcoidosis
pulmonary sarcoidosissource ↗
◆FDA Feedback ReceivedEfzofitimod/kgFDA Meeting
Planned FDA meeting to review EFZO-FIT results and determine path forward
pulmonary sarcoidosissource ↗
▲Poster PresentationEfzofitimod/kgPresentation
EFZO-FIT subgroup analysis findings presented at WASOG 2026 Congress
pulmonary sarcoidosis with restrictive lung diseasesource ↗
▲Subgroup AnalysisEfzofitimod/kgClinical Data
Subgroup analysis of EFZO-FIT showed clinically meaningful FVC benefit in restrictive lung disease patients treated with 5.0 mg/kg efzofitimod
pulmonary sarcoidosis with restrictive lung diseasesource ↗
▼IP Litigation RulingIP / Competition
Securities class action lawsuit moves forward; lead plaintiff deadline Dec 8, 2025
◆Oral PresentationEfzofitimod/kgPresentation
Late-breaking oral presentation of additional findings from Phase 3 EFZO-FIT study at ERS Congress 2025
pulmonary sarcoidosissource ↗
▼Topline ReadoutEfzofitimod/kgClinical Data
Topline results from Phase 3 EFZO-FIT study (previously reported)
pulmonary sarcoidosissource ↗
▼Primary Endpoint MissedEfzofitimod/kgClinical Data
Phase 3 EFZO-FIT study did not meet primary endpoint of change from baseline in mean daily oral corticosteroid dose at week 48
pulmonary sarcoidosissource ↗
●Oral PresentationEfzofitimod/kgPresentation
Late-breaking oral presentation of EFZO-FIT results at European Respiratory Society Congress 2025
pulmonary sarcoidosissource ↗
▼Primary Endpoint MissedEfzofitimod/kgClinical Data
EFZO-FIT study did not meet primary endpoint in change from baseline in mean daily OSC dose at week 48
pulmonary sarcoidosissource ↗
▼Topline ReadoutEfzofitimod/kgClinical Data
Topline results for Phase 3 EFZO-FIT study of Efzofitimod in pulmonary sarcoidosis
pulmonary sarcoidosissource ↗
◆FDA Feedback ReceivedEfzofitimod/kgFDA Meeting
Engage with FDA to determine path forward after disappointing topline results
pulmonary sarcoidosissource ↗
▼Full ResultsEfzofitimod/kgClinical Data
EFZO-FIT study results: efzofitimod failed to show change in mean daily OCS dose at week 48
pulmonary sarcoidosissource ↗
▼Topline ReadoutEfzofitimod/kgClinical Data
Phase 3 EFZO-FIT topline results for efzofitimod in pulmonary sarcoidosis
pulmonary sarcoidosissource ↗
▼Primary Endpoint MissedEfzofitimod/kgClinical Data
Phase 3 EFZO-FIT study did not meet primary endpoint of change from baseline in mean daily oral corticosteroid dose at week 48
pulmonary sarcoidosissource ↗
▲Last Patient Last VisitEfzofitimod/kgTrial
Completed last patient visit in Phase 3 EFZO-FIT study
pulmonary sarcoidosissource ↗
▲Interim AnalysisEfzofitimod/kgTrial
Announced interim data from Phase 2 EFZO-CONNECT study
systemic sclerosis-related ILD (SSc-ILD)source ↗
▼Equity OfferingCorporate
Raised approximately $30.7 million in gross proceeds from ATM offering
▲Last Patient Last VisitEfzofitimod/kgTrial
Last patient completed last visit in Phase 3 EFZO-FIT study
pulmonary sarcoidosissource ↗
◆Topline ReadoutEfzofitimod/kgClinical Data
Pivotal Phase 3 data for efzofitimod in pulmonary sarcoidosis
pulmonary sarcoidosissource ↗
▼Primary Endpoint MissedEfzofitimod/kgClinical Data
EFZO-FIT primary endpoint not met
pulmonary sarcoidosissource ↗
Past FDA Catalysts and PDUFA Decisions
How ATYR actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-07-16 | efzofitimod | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
D39 / 100
Pipeline Score
$6M
Pipeline Value
Overvalued
Valuation Signal
2
Drugs Scored
0.2x
rNPV / MCap
Top 40%
Micro Cap(rank 264 of 658)
Percentile Rank
aTyr Pharma, Inc. faces pipeline headwinds (39/100), with $141M risk-adjusted pipeline value, led by Efzofitimod/kg in Pulmonary Sarcoidosis (Phase 3).
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Efzofitimod/kg Small moleculeCompletedNCT05415137 | Pulmonary Sarcoidosis | Phase 3 | COMPLETED | 268 | Jul 14, 2025 |
Clinical Trial Results
Readouts, endpoints and source filings for every ATYR program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| efzofitimod | pulmonary sarcoidosis | Phase 3 | 2026-03-05 | 268 patients; 3.0 mg/kg and 5.0 mg/kg; did not meet its primary endpoint; p=0.0479; p=0.0226; p=0.0197; p=0.0196Read More | Ashlee Dunston Sr. Director, Investor Relations and Public Affairs adunston@atyrpharma.com aTyr Pharma Announces Fourth Quarter and Full Year 2025 Results and Provides Corporate Update Company scheduled to meetRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| SCHIMMEL PAULDirector | Buy | 100,000 779,143 held | $0.50 | 05/27/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in ATYR
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| SILVERARC CAPITAL MANAGEMENT, LLC | 0.1 % | 901.00 K | 1.25 M |
ATYR Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-20 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How ATYR ranks across every disease it competes in
Competitive Position is a premium feature
See how ATYR ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialATYR News
ATYR▼ -10%on this news
aTyr Pharma Announces Alignment with FDA on Phase 3 Study of Efzofitimod in Pulmonary Sarcoidosis
aTyr Pharma has announced alignment with the FDA on the protocol for a Phase 3 study of efzofitimod in patients with pulmonary sarcoidosis. The global study will evaluate the drug's efficacy and safety, focusing on forced vital capacity as the primary endpoint. The company plans to initiate study-related activities in Q4 2026, supported by positive data from earlier studies.
Read more →ATYRaTyr Pharma Provides Update on Timing of Regulatory Response for Planned Phase 3 Study of Efzofitimod in Pulmonary Sarcoidosis
aTyr Pharma has provided an update regarding the anticipated timing of the FDA's response to its protocol for a Phase 3 study of efzofitimod in patients with pulmonary sarcoidosis. The company expects to receive feedback by mid-September 2026. The planned study aims to evaluate the drug's efficacy and safety in a global, randomized trial involving approximately 372 patients.
Read more →ATYRaTyr Pharma Announces Second Quarter 2026 Results, Program Prioritization and Corporate Restructuring to Support Efzofitimod Program in ILD
aTyr Pharma has announced its second quarter 2026 results, highlighting a corporate restructuring to prioritize the efzofitimod program for interstitial lung disease. The company has completed enrollment in a Phase 2 study and is awaiting FDA feedback on a planned Phase 3 study protocol for pulmonary sarcoidosis. Despite a significant workforce reduction, aTyr maintains a strong cash position, expected to last into late 2028.
Read more →ATYR▲ +9.9%on this newsshared move
aTyr Pharma to Present Subgroup Analysis of Phase 3 EFZO-FIT™ Study of Efzofitimod in Pulmonary Sarcoidosis at WASOG 2026
aTyr Pharma announced a subgroup analysis of its Phase 3 EFZO-FIT study of efzofitimod in pulmonary sarcoidosis, showing significant benefits in lung function and patient-reported outcomes. The analysis included patients with restrictive lung disease, highlighting the potential of efzofitimod as a treatment option. The company has also submitted a protocol for a planned Phase 3 study to the FDA.
Read more →ATYRaTyr Pharma Advancing tRNA synthetase biology Efzofitimod in Pulmonary Sarcoidosis and Beyond June 2026 2026 aTyr Pharma Exhibit 99.1
aTyr Pharma has made strides in advancing efzofitimod, an immunomodulator targeting pulmonary sarcoidosis, while acknowledging risks in forward-looking statements. The recent EFZO-FIT study involved the largest cohort ever in this area but did not meet its primary endpoint. However, findings suggest that patients can manage symptoms on lower doses of corticosteroids without worsening disease. The company is focusing on addressing the significant unmet medical need in this orphan disease with no FDA-approved therapies for over 70 years.
Read more →ATYR▼ -10%on this news
aTyr Pharma Announces First Quarter 2026 Results and Provides Corporate Update
aTyr Pharma has announced its first quarter 2026 results, highlighting continued development of efzofitimod for pulmonary sarcoidosis after a positive FDA Type C meeting. The company plans to submit an IND application in June 2026 for a new Phase 3 study targeting chronic symptomatic pulmonary sarcoidosis. Furthermore, aTyr is on track to complete enrollment in a Phase 2 study for systemic sclerosis-related interstitial lung disease within the first half of 2026. The financial outlook shows a healthy cash position of $68.3 million.
Read more →ATYR▼ -10%on this news
aTyr Pharma Announces First Quarter 2026 Results and Provides Corporate Update Company to continue development of efzofitimod in pulmonary sarcoidosis following Type C meeting with the FDA.
aTyr Pharma announced its first quarter 2026 results, highlighting continued development of efzofitimod for pulmonary sarcoidosis after a Type C meeting with the FDA. The company plans to file an IND in June 2026 for a Phase 3 study targeting chronic, symptomatic patients. Additionally, they are on track to complete enrollment in a Phase 2 study focused on systemic sclerosis-related interstitial lung disease by the first half of 2026, with a solid financial position of $68.3 million reported at the end of Q1 2026.
Read more →ATYR▼ -25.3%on this newsshared move
aTyr Pharma to Participate in Upcoming Investor Conferences
aTyr Pharma, Inc. will be participating in two investor conferences in May and June 2026, aimed at enhancing investor relations. The conferences are the RBC Capital Markets Global Healthcare Conference and the Jefferies Global Healthcare Conference, where company management, including President and CEO Sanjay S. Shukla, will engage with investors through presentations and one-on-one meetings. aTyr focuses on developing first-in-class therapies using its unique tRNA synthetase platform for conditions like interstitial lung disease.
Read more →ATYRaTyr Pharma Advancing tRNA synthetase biology Efzofitimod in Pulmonary Sarcoidosis and Beyond May 11, 2026 2026 aTyr Pharma Exhibit 99.1
aTyr Pharma is advancing its development of efzofitimod for pulmonary sarcoidosis following a positive FDA Type C meeting. The meeting affirmed the use of forced vital capacity (FVC) and King's Sarcoidosis Questionnaire-Lung (KSQ-L) as endpoints. Despite the previous trial's primary endpoint miss, efzofitimod exhibited a sound safety profile, leading the company to initiate a new Phase 3 study (C-006) employing FDA recommendations. The future study aims to focus on a more homogeneous patient population to enhance the efficacy evaluation.
Read more →ATYRaTyr Pharma Provides Regulatory and Clinical Update for Efzofitimod in Pulmonary Sarcoidosis Following FDA Type C Meeting
aTyr Pharma has outlined its plans for efzofitimod in pulmonary sarcoidosis following positive feedback from the FDA. The company aims to submit an IND application in June 2026 for a new Phase 3 study focusing on patients with restrictive lung disease. Key endpoints will include forced vital capacity (FVC) and the King's Sarcoidosis Questionnaire (KSQ)-Lung score. Management expressed confidence in the drug's safety and efficacy, while adjusting the dosing schedule to improve patient outcomes.
Read more →ATYR▼ -6.4%on this news
aTyr Pharma Announces Fourth Quarter and Full Year 2025 Results and Provides Corporate Update
aTyr Pharma released its financial and operational update for 2025, highlighting the results from its Phase 3 EFZO-FIT™ study for efzofitimod in pulmonary sarcoidosis. The study marked a significant milestone for the company, even as it fell short of its primary efficacy endpoint. The company has scheduled a Type C meeting with the FDA to discuss the study's results and next steps, while also progressing with enrollment in its Phase 2 EFZO-CONNECT™ study for systemic sclerosis-related interstitial lung disease. aTyr ended the year with substantial cash reserves of $80.9 million.
Read more →ATYRaTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
aTyr Pharma has announced the granting of nonstatutory stock options to two new employees, totaling 12,200 shares, as part of its inducement plan under Nasdaq Listing Rule 5635(c)(4). The options have an exercise price of $0.98 per share, matching the closing price on February 17, 2026. Each option will vest over four years, encouraging long-term employment. aTyr continues to focus on leveraging its tRNA synthetase platform for the development of novel therapies, including its lead candidate, efzofitimod, for interstitial lung disease.
Read more →ATYRaTyr Pharma to Present at the Leerink Partners Global Healthcare Conference
aTyr Pharma, a clinical stage biotechnology company, will present at the Leerink Partners Global Healthcare Conference from March 8-11, 2026, in Miami, FL. CEO Sanjay S. Shukla will lead the presentation on the company's advancements in tRNA synthetase-based therapies. Investors can also schedule one-on-one meetings with the management team. A webcast of the presentation will be available on their website.
Read more →ATYRaTyr Pharma Announces Scheduling of FDA Type C Meeting to Discuss Efzofitimod Program in Pulmonary Sarcoidosis
aTyr Pharma announced a Type C meeting with the FDA scheduled for mid-April 2026 to discuss the efzofitimod program for pulmonary sarcoidosis. The Phase 3 EFZO-FIT study showed clinical benefits despite not meeting its primary endpoint. The company aims to determine the next steps for efzofitimod following the meeting.
Read more →ATYRaTyr Pharma to Present at Piper Sandler 37th Annual Healthcare Conference
aTyr Pharma will present at the Piper Sandler 37th Annual Healthcare Conference on December 2, 2025. CEO Sanjay S. Shukla will lead the presentation, which will be available via webcast. The company is focused on developing therapies from its tRNA synthetase platform, particularly for interstitial lung disease.
Read more →ATYR▲ +6%on this newsshared move
aTyr Pharma Announces Third Quarter 2025 Results and Provides Corporate Update
aTyr Pharma reported its third quarter 2025 results, highlighting the Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis. Although the primary endpoint was not achieved, the therapy showed potential benefits in improving patient quality of life. The company plans to consult with the FDA in early 2026 to discuss next steps for efzofitimod.
Read more →ATYR▼ -9.3%on this newsshared move
aTyr Pharma Presents Additional Findings from Phase 3 EFZO-FIT™ Study in Late-Breaking Oral Abstract at the European Respiratory Society (ERS) Congress 2025
aTyr Pharma presented additional findings from the Phase 3 EFZO-FIT™ study at the ERS Congress 2025, highlighting significant clinical benefits of efzofitimod in patients with pulmonary sarcoidosis. Improvements were noted in fatigue and general health scores, despite not meeting the primary endpoint. The findings suggest efzofitimod's potential to enhance quality of life and reduce steroid dependence.
Read more →ATYR▼ -83.2%on this newsshared move
aTyr Pharma Announces Topline Results from Phase 3 EFZO-FIT™ Study of Efzofitimod in Pulmonary Sarcoidosis
aTyr Pharma announced topline results from the Phase 3 EFZO-FIT study of efzofitimod in pulmonary sarcoidosis. The study did not meet its primary endpoint regarding corticosteroid dose reduction, but showed clinical benefits including improved KSQ-Lung scores and a higher rate of steroid withdrawal in the treatment group. The company plans to engage with the FDA to discuss the future of efzofitimod in this indication.
Read more →About aTyr Pharma, Inc.
Headquarters10240 SORRENTO VALLEY ROAD, SAN DIEGO, CA, 92121
BIOPHARMAWATCH ELITE PLUS
Trade the next ATYR catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime